Within the Winter 2022 version of “European Biotechnology“ journal, from December, the quilt story “Biotech Financing – Disaster? What Disaster?” focuses on 2022 as “probably the most tough yr for mergers and acquisitions in biotech since 2018…”

In an interview with Dr. Georg Kääb, our CEO, Arno Fuchs, describes his view on the present improvement within the US and Europe.  

Learn the total article on right here.

Leave a Reply

Your email address will not be published.